

## Subject: Production discontinued for Evzio<sup>®</sup> naloxone auto-injector and its generic equivalent

Kaléo, the makers of Evzio<sup>®</sup>, have recently discontinued the production of the Evzio<sup>®</sup> naloxone auto-injector and its generic equivalent. The FDA Orange Book now lists the brand and generic products with “discontinued” marketing statuses. The FDA approved Evzio<sup>®</sup> auto-injector to temporarily reverse the effects of an opioid overdose. The drug is designed to be administered outside of the health care setting by family members or caregivers.

Alternative naloxone products such as Narcan nasal spray continue to be available for use in an overdose situation. In the workers’ compensation industry, injured workers may have been prescribed the naloxone auto-injector along with an opioid prescription. The reason for discontinuation of the auto-injectors is unknown; however, the existing product will remain in pharmacies and Kaléo did not express concerns regarding continued use of the product through the expiration date. First Script will continue to monitor the situation and provide updates where relevant.

For more information, please contact your Account Manager or Account Pharmacist or email us at [askthepharmacist@cvtv.us.com](mailto:askthepharmacist@cvtv.us.com).